Placebo matching vicadrostat
Sponsors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim
Conditions
Cardiovascular DiseasesChronic Kidney DiseaseDiabetes Mellitus, Type 2Heart failureHypertensionType 2 diabetescardiovascular diseasechronic kidney disease
Phase 2
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease
Active, not recruitingNCT06926660
Start: 2025-07-18End: 2026-08-20Target: 416Updated: 2026-04-02
A Phase II randomised, double-blind, parallel-group, multicentre, international trial to investigate the safety and efficacy of vicadrostat and empagliflozin administered with simultaneous vs staggered initiation in participants with chronic kidney disease at risk of kidney disease progression
RecruitingCTIS2024-518457-42-00
Start: 2025-08-28Target: 100Updated: 2025-08-11
Phase 3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RecruitingNCT07064473
Start: 2025-05-09End: 2029-12-21Target: 11800Updated: 2026-04-02
EASi-HF Reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%
RecruitingCTIS2024-519525-38-00
Start: 2025-08-22Target: 1539Updated: 2026-01-12
A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease
RecruitingCTIS2025-521188-11-00
Start: 2025-10-15Target: 4576Updated: 2026-01-27